Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments

v3.19.3
Note 15 - Segments
9 Months Ended
Sep. 30, 2019
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
1
5
.
Segments
 
We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were
no
inter-segment sales. We manage our business based on
two
primary types of drug products: (i) diagnostic substances, including Tc
99m
tilmanocept and other diagnostic applications of our Manocept platform, and
NAV4694
(sublicensed in
April 2018),
and (ii) therapeutic development programs, including therapeutic applications of our Manocept platform.
 
The information in the following tables is derived directly from each reportable segment’s financial reporting.
 
Three Months Ended September
30
, 2019
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
4,895
    $
    $
    $
4,895
 
Grant and other revenue
   
77,049
     
154,867
     
     
231,916
 
Total revenue
   
81,944
     
154,867
     
     
236,811
 
Cost of revenue
   
195
     
     
     
195
 
Research and development expenses
   
1,678,423
     
123,135
     
     
1,801,558
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
1,052
     
1,484,155
     
1,485,207
 
Depreciation and amortization
(2)
   
     
     
34,289
     
34,289
 
(Loss) income from operations
(3)
   
(1,596,674
)
   
30,680
     
(1,518,444
)
   
(3,084,438
)
Other income
(4)
   
     
     
10,334
     
10,334
 
Income tax (expense) benefit
   
(72
)
   
16
     
55
     
 
Net (loss) income
   
(1,596,746
)
   
30,696
     
(1,508,055
)
   
(3,074,104
)
Total assets, net of depreciation and amortization:
                               
United States
  $
36,811
    $
93,860
    $
4,688,379
    $
4,819,050
 
International
   
2,606
     
     
     
2,606
 
Capital expenditures
   
     
     
     
 
 
T
hree Months Ended September 30, 2018
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
2,382
    $
    $
    $
2,382
 
License revenue
   
19,930
     
     
     
19,930
 
Grant and other revenue
   
65,505
     
143,641
     
     
209,146
 
Total revenue
   
87,817
     
143,641
     
     
231,458
 
Cost of revenue
   
38,101
     
     
     
38,101
 
Research and development expenses
   
711,355
     
514,415
     
     
1,225,770
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
20,532
     
2,630,581
     
2,651,113
 
Depreciation and amortization
(2)
   
     
     
37,590
     
37,590
 
Loss from operations
(3)
   
(661,639
)
   
(391,306
)
   
(2,668,171
)
   
(3,721,116
)
Other expense
(4)
   
     
     
(24,534
)
   
(24,534
)
Income tax expense
   
(10,081
)
   
(3,879
)
   
(62,299
)
   
(76,259
)
Net loss
   
(671,720
)
   
(395,185
)
   
(2,755,004
)
   
(3,821,909
)
Total assets, net of depreciation and amortization:
                               
United States
  $
117,722
    $
72,622
    $
8,899,301
    $
9,089,645
 
International
   
18,239
     
     
1,158
     
19,397
 
Capital expenditures
   
     
     
16,152
     
16,152
 
 
Nine
Months Ended
September
30, 2019
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
13,985
    $
    $
    $
13,985
 
License revenue
   
9,953
     
     
     
9,953
 
Grant and other revenue
   
309,670
     
204,919
     
     
514,589
 
Total revenue
   
333,608
     
204,919
     
     
538,527
 
Cost of revenue
   
6,559
     
     
     
6,559
 
Research and development expenses
   
3,194,468
     
418,315
     
     
3,612,783
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
15,828
     
4,985,990
     
5,001,818
 
Depreciation and amortization
(2)
   
     
     
107,794
     
107,794
 
Loss from operations
(3)
   
(2,867,419
)
   
(229,224
)
   
(5,093,784
)
   
(8,190,427
)
Other income
(4)
   
     
     
17,456
     
17,456
 
Provision for income tax
   
(248
)
   
(20
)
   
(439
)
   
(707
)
Net loss from continuing operations
   
(2,867,667
)
   
(229,244
)
   
(5,076,767
)
   
(8,173,678
)
Loss from discontinued operations, net of tax
   
(2,665
)
   
     
     
(2,665
)
Net loss
   
(2,870,332
)
   
(229,244
)
   
(5,076,767
)
   
(8,176,343
)
Total assets, net of depreciation and amortization:
                               
United States
  $
36,811
    $
93,860
    $
4,688,379
    $
4,819,050
 
International
   
2,606
     
     
     
2,606
 
Capital expenditures
   
     
     
     
 
 
Nine Months Ended September 30, 2018
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
9,842
    $
    $
    $
9,842
 
License revenue
   
277,639
     
     
     
277,639
 
Grant and other revenue
   
454,830
     
307,719
     
     
762,549
 
Total revenue
   
742,311
     
307,719
     
     
1,050,030
 
Cost of revenue
   
73,811
     
     
     
73,811
 
Research and development expenses
   
2,409,524
     
957,920
     
     
3,367,444
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
45,769
     
6,095,617
     
6,141,386
 
Depreciation and amortization
(2)
   
     
     
113,088
     
113,088
 
Loss from operations
(3)
   
(1,741,024
)
   
(695,970
)
   
(6,208,705
)
   
(8,645,699
)
Other expense
(4)
   
     
     
(4,284,014
)
   
(4,284,014
)
Income tax expense
   
(8,797
)
   
(3,517
)
   
(53,017
)
   
(65,330
)
Net loss from continuing operations
   
(1,749,821
)
   
(699,487
)
   
(10,545,736
)
   
(12,995,043
)
Loss from discontinued operations, net of tax
   
(1,938
)
   
     
     
(1,938
)
Gain on sale of discontinued operations, net of tax
   
43,053
     
     
     
43,053
 
Net loss
   
(1,708,706
)
   
(699,487
)
   
(10,545,736
)
   
(12,953,928
)
Total assets, net of depreciation and amortization:
                               
United States
  $
117,722
    $
72,622
    $
8,899,301
    $
9,089,645
 
International
   
18,239
     
     
1,158
     
19,397
 
Capital expenditures
   
     
     
19,317
     
19,317
 
 
 
(
1
)
General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are
not
currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
 
(
2
)
Depreciation and amortization is reflected in selling, general and administrative expenses (
$34,289
and
$37,590
for the
three
-month periods ended
September 30, 2019
and
2018,
and
$107,794
and
$113,088
for the
nine
-month periods ended
September 30, 2019
and
2018,
respectively).
 
(
3
)
Loss from operations does
not
reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
 
(
4
)
Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are
not
currently allocated to our individual reportable segments.